BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 11:53 am Sale |
2022-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BIOTECHNOLOGY VALUE FUND L P | 1,451,197 2.100% |
-3,480,682 (-70.58%) |
Filing |
| 2022-02-14 1:12 pm Purchase |
2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BIOTECHNOLOGY VALUE FUND L P | 4,931,879 8.900% |
1,221,190 (+32.91%) |
Filing |
| 2021-02-12 5:16 pm Purchase |
2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
BIOTECHNOLOGY VALUE FUND L P | 3,710,689 7.400% |
894,299 (+31.75%) |
Filing |